Your browser doesn't support javascript.
Prevalence and prospective evaluation of cognitive dysfunctions after SARS due to SARS-CoV-2 virus. The COgnitiVID study.
Vialatte de Pémille, C; Ray, A; Michel, A; Stefano, F; Yim, T; Bruel, C; Zuber, M.
  • Vialatte de Pémille C; Neurological department, groupe hospitalier Paris Saint-Joseph, Paris, France; Université Paris Cité, Paris, France. Electronic address: cvialatte@ghpsj.fr.
  • Ray A; Neurological department, groupe hospitalier Paris Saint-Joseph, Paris, France; Université Paris Cité, Paris, France.
  • Michel A; Neurological department, groupe hospitalier Paris Saint-Joseph, Paris, France.
  • Stefano F; Neurological department, groupe hospitalier Paris Saint-Joseph, Paris, France.
  • Yim T; Neurological department, groupe hospitalier Paris Saint-Joseph, Paris, France.
  • Bruel C; Intensive care unit, groupe hospitalier Paris Saint-Joseph, Paris, France.
  • Zuber M; Neurological department, groupe hospitalier Paris Saint-Joseph, Paris, France; Université Paris Cité, Paris, France.
Rev Neurol (Paris) ; 178(8): 802-807, 2022 Oct.
Article in English | MEDLINE | ID: covidwho-1851876
ABSTRACT

OBJECTIVE:

COVID-19 due to SARS-CoV-2 virus is a new cause of severe acute respiratory syndrome (SARS). Little is known about the short-term cognitive prognosis for these patients. We prospectively evaluated basic cognitive functions shortly after care in the intensive care unit (ICU) and three months later in post-ICU COVID-19 patients. MATERIAL AND

METHODS:

We performed a prospective single-center study in our institution in Paris. Patients with SARS-CoV-2 SARS were prospectively recruited via our ICU. Patients were evaluated using standardized cognitive tests at baseline and at three months' follow-up. Our primary endpoint was the evolution of the following five global tests MMSE, FAB, oral naming test, Dubois five words test and MADRS.

RESULTS:

We explored 13 patients at baseline and follow-up. All patients had cognitive impairment at baseline but they all improved at three months, significantly on two of the five global tests after Bonferroni correction for multiple testing MMSE (median 18 (IQR [15-22]) and 27 (IQR [27-29]) respectively, P=0.002) and FAB test (median 14 (IQR [14-17]) and 17 (IQR [17,18]) respectively, P=0.002).

CONCLUSIONS:

We report here the first longitudinal data on short-term cognitive impairment after intensive care in COVID-19 patients. We found acute and short-term cognitive impairment but significant improvement at three months. This pattern does not seem to differ from other causes of post-intensive care syndrome.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cognitive Dysfunction / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Rev Neurol (Paris) Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cognitive Dysfunction / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Rev Neurol (Paris) Year: 2022 Document Type: Article